Key Highlights

  • Kodiak Sciences' two candidates met Phase 3 non-inferiority endpoints in wAMD.
  • Adicet Bio reported a 54% DORIS remission rate in lupus.
  • SCYNEXIS secured a BARDA award of up to $214 million.
  • The FDA lifted the exposure cap on CervoMed's neflamapimod.
  • Moleculin reported zero cardiotoxicity across pooled Annamycin studies.

Biotech Stocks in Focus Ahead of the Opening Bell

The biotechnology sector has a busy pre-market session. Late-stage clinical readouts, early-stage efficacy data, government funding, regulatory updates and a MedTech imaging Partnership are all driving attention. Ophthalmology, autoimmune disease, antifungals, neurology, oncology and metabolic disorders are all represented, showing how varied the catalysts are across small- and mid-cap biotech names.

Here is a closer look at the companies making news.

Kodiak Sciences (NASDAQ: KOD): Phase 3 DAYBREAK Success in wAMD

Kodiak Sciences (NASDAQ: KOD) reported positive Phase 3 DAYBREAK data in wet age-related macular degeneration (wAMD). Both of its candidates, Zenkuda and tabirafusp-ted, met their non-inferiority primary endpoints against aflibercept, an established standard of care.

Zenkuda also showed rapid retinal drying. In addition, 54% of patients treated with Zenkuda reached a six-month dosing interval. Longer dosing intervals are a key goal in retinal disease, because they can reduce the frequency of injections patients need.

The data support Kodiak's plan to submit a multi-indication Biologics License Application (BLA) in Q4 2026. The planned filing would cover wAMD, diabetic retinopathy and retinal vein occlusion.

Adicet Bio (NASDAQ: ACET): Strong Early Data in Lupus

Adicet Bio (NASDAQ: ACET) released Phase 1 findings for prula-cel in systemic lupus erythematosus, with or without lupus nephritis.

The therapy delivered a 54% DORIS remission rate and a 50% complete renal response at 12 months. Every patient in the study discontinued immunosuppressant therapy, which is a notable outcome in a disease that often requires long-term immune suppression.

The safety profile was favorable. No cases of ICANS, IEC-HS or Grade 3 or higher cytokine release syndrome (CRS) were reported. These are side effects commonly watched for in cell therapies.

Based on these results, Adicet is targeting initiation of a pivotal lupus nephritis trial in Q4 2026. The company may also pursue development in non-renal lupus, pending alignment with the FDA.

SCYNEXIS (NASDAQ: SCYX): BARDA Award Extends Cash Runway

SCYNEXIS (NASDAQ: SCYX) obtained an award from the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $214 million in non-dilutive capital. The funding will advance SCY-247, the company's Phase 2-ready antifungal agent.

The award includes an upfront allocation of $18.5 million for oral and intravenous clinical work in invasive candidiasis. If all Options are exercised, the contract could fund development up to an NDA filing across two targeted indications.

The award leaves the company's planned SCY-770 pipeline intact. It also extends SCYNEXIS' estimated cash runway through 2029. Non-dilutive funding matters for small biotechs, as it lets them advance programmes without issuing new shares.

CervoMed (NASDAQ: CRVO): FDA Lifts Neflamapimod Exposure Cap

CervoMed (NASDAQ: CRVO) disclosed favorable Phase 1 pharmacokinetic results for an upgraded 50 mg tablet formulation of neflamapimod.

Following the data, the FDA lifted the drug's previous exposure cap. This clears the way for higher-dose evaluation in dementia with Lewy bodies.

The new tablet produced roughly 20% lower peak levels and 20% higher trough levels. This profile supports a planned 100 mg twice-daily regimen, which is expected to raise trough exposure by 33% compared with earlier therapeutic doses. The new formulation also resolves previous production inconsistencies.

Moleculin Biotech (NASDAQ: MBRX): Annamycin Shows Clean Cardiac Profile

Moleculin Biotech (NASDAQ: MBRX) published peer-reviewed pooled cardiac safety data for Annamycin. The analysis covered five clinical studies and 90 subjects with acute myeloid leukemia (AML) or metastatic soft tissue sarcoma.

The findings showed zero clinical or subclinical cardiotoxicity, even at cumulative doses above traditional anthracycline thresholds. Heart damage is a well-known limitation of conventional anthracyclines, so this profile could be an important differentiator.

An independent assessment from Cleveland Clinic reinforced Annamycin's distinct cardiac profile. The drug continues to advance in the pivotal MIRACLE protocol for relapsed or refractory AML.

MediciNova (NASDAQ: MNOV): Mixed Phase 2 Results for MN-001

MediciNova (NASDAQ: MNOV) announced Phase 2 topline results for MN-001 in patients with non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia with type 2 diabetes.

The study showed an early, statistically significant decline in triglycerides at Week 4. It also showed significant gains in HDL-C and HDL-P at Week 24.

The 40-patient exploratory trial showed favorable safety and favorable numerical trends in weight and liver fat. However, it did not demonstrate statistically significant separation at Week 24 for the liver-fat or triglyceride endpoints. The mixed readout is likely to shape how investors view the programme's next steps.

Accuray (NASDAQ: ARAY): Samsung NeuroLogica Imaging Partnership

Accuray (NASDAQ: ARAY) entered into a strategic partnership with Samsung NeuroLogica. The collaboration will integrate enhanced volumetric imaging features into the CyberKnife robotic radiosurgery system.

The effort aims to improve target visualization, support better clinical decision-making and enable future adaptive radiation therapy workflows. Development will proceed in structured phases. Financial terms and commercial launch timelines were not disclosed.

What These Updates Mean for Biotech Investors

Today's news flow covers the full range of biotech catalysts. Kodiak's Phase 3 success and planned BLA represent a late-stage regulatory milestone. Adicet's early lupus data and CervoMed's FDA update point to upcoming clinical progress. SCYNEXIS' BARDA award strengthens its balance sheet, while Moleculin's safety data supports its pivotal programme.

MediciNova's mixed results are a reminder that exploratory trials often produce uneven outcomes. Accuray's partnership adds a medtech angle to the session.

As always, early-stage data carry uncertainty, and pre-market interest does not always carry through the trading day. Investors may want to review each company's full disclosures before making decisions.